Impact of glucocorticoids on clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer

GUO Huaijuan; MAO Jingxian; WANG Jiaxin; YAN Xuebing; WANG Ying

doi:10.7619/jcmp.20223251

Journal of Clinical Medicine in Practice > 2023 > 27(1): 31-37. > DOI: 10.7619/jcmp.20223251

GUO Huaijuan, MAO Jingxian, WANG Jiaxin, YAN Xuebing, WANG Ying. Impact of glucocorticoids on clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2023, 27(1): 31-37. DOI: 10.7619/jcmp.20223251

Citation:

PDF (1393 KB)

Impact of glucocorticoids on clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer

Department of Oncology, the Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, 225000

More Information

Received Date: October 31, 2022
Available Online: February 01, 2023

Graphical Abstract

Abstract

Abstract

Objective
To evaluate the impact of glucocorticoids (GC) on the clinical efficacy of immune checkpoint inhibitors (ICI) in treating non-small cell lung cancer (NSCLC).
Methods
The clinical data of 131 patients with advanced NSCLC who received ICI treatment in the Affiliated Hospital of Yangzhou University were retrospectively analyzed. They were divided into GC group (n=79) and non-GC group (n=52) according to whether they used GC (≥ 10 mg/d prednisone or equivalent GC) within 3 months before and after ICI treatment or not. The GC group was divided into four subgroups according to the following indications: non-cancer indications group, cancer indications group, immune related adverse events (irAEs) group and pre-chemotherapy treatment group. The correlation between GC usage and the clinical characteristics of patients was analyzed. The Kaplan-Meier survival curve was used to analyze the impact of GC use on overall survival (OS) and progression-free survival (PFS). The univariate and multivariate analysis based on Cox hazard proportional regression models were used to identify whether GC use was a prognostic factor.
Results
No significant correlations were found between GC use and age (χ²=0.180, P=0.672), gender (χ²=3.179, P=0.075), smoking (χ²=0.579, P=0.447), pathological type (χ²=0.628, P=0.428), the score of United States Eastern Collaborative Group(ECOG) (χ²=0.074, P=0.785) score and treatment lines (χ²=1.853, P=0.173), while it was correlated with treatment strategies (χ²=3.998, P=0.046). The OS and PFS of the GC group were shorter when compared with the non-GC group, and the differences were statistically significant (P < 0.05). The multivariate analysis showed that GC use was an independent influencing factor for OS (HR=1.82, P=0.026) and PFS (HR=1.76, P=0.012). The subgroup analysis demonstrated that patients receiving GC for cancer related indications had shorter OS (P=0.006) and PFS (P=0.011) than those receiving GC for non-cancer indications, irAEs, and pre-chemotherapy treatment. The multivariate analysis showed that GC use for cancer related indications was an independent risk factor for OS (P=0.001) and PFS (P=0.005).
Conclusion
The GC use is negatively correlated with the clinical efficacy of ICI in treating patients with advanced NSCLC, especially for those receiving GC for cancer-related indications. GC should be used cautiously in ICI-treated NSCLC patients.
- glucocorticoids,
- non-small cell lung cancer,
- prognosis,
- immune checkpoint inhibitor,
- risk factors,
- single factor analysis,
- multifactor analysis

FullText(HTML)

References (33)

References

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	ZHENG R S, ZHANG S W, ZENG H M, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9. doi: 10.1016/j.jncc.2022.02.002
[3]	DUMA N, SANTANA-DAVILA R, MOLINA J R. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment[J]. Mayo Clin Proc, 2019, 94(8): 1623-1640. doi: 10.1016/j.mayocp.2019.01.013
[4]	TOPALIAN S L, BRAHMER J R, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab[J]. JAMA Oncol, 2019, 5(10): 1411-1420. doi: 10.1001/jamaoncol.2019.2187
[5]	GARON E B, HELLMANN M D, RIZVI N A, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study[J]. J Clin Oncol, 2019, 37(28): 2518-2527. doi: 10.1200/JCO.19.00934
[6]	SHI T, MA Y Y, YU L F, et al. Cancer immunotherapy: a focus on the regulation of immune checkpoints[J]. Int J Mol Sci, 2018, 19(5): 1389. doi: 10.3390/ijms19051389
[7]	郭怀娟, 杨梦雪, 童建东, 等. 临床药物对免疫检查点抑制剂抗肿瘤效果影响的研究进展[J]. 实用临床医药杂志, 2022, 26(1): 120-122, 133. doi: 10.7619/jcmp.20212975
[8]	YANG M X, WANG Y, YUAN M, et al. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: an up-to-date systematic review and meta-analysis[J]. Int Immunopharmacol, 2020, 88: 106876. doi: 10.1016/j.intimp.2020.106876
[9]	LIU C X, GUO H J, MAO H Y, et al. An up-to-date investigation into the correlation between proton pump inhibitor use and the clinical efficacy of immune checkpoint inhibitors in advanced solid cancers: a systematic review and meta-analysis[J]. Front Oncol, 2022, 12: 753234. doi: 10.3389/fonc.2022.753234
[10]	CORTELLINI A, TUCCI M, ADAMO V, et al. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice[J]. J Immunother Cancer, 2020, 8(2): e001361. doi: 10.1136/jitc-2020-001361
[11]	METRO G, BANNA G L, SIGNORELLI D, et al. Efficacy of pembrolizumab monotherapy in patients with or without brain metastases from advanced non-small cell lung cancer with a PD-L1 expression ≥ 50%[J]. J Immunother, 2020, 43(9): 299-306. doi: 10.1097/CJI.0000000000000340
[12]	SAKURADA T, NOKIHARA H, KOGA T, et al. Prevention of pemetrexed-induced rash using low-dose corticosteroids: a phase Ⅱ study[J]. Oncologist, 2022, 27(7): e554-e560. doi: 10.1093/oncolo/oyab077
[13]	LANSINGER O M, BIEDERMANN S, HE Z H, et al. Do steroids matter A retrospective review of premedication for taxane chemotherapy and hypersensitivity reactions[J]. J Clin Oncol, 2021, 39(32): 3583-3590. doi: 10.1200/JCO.21.01200
[14]	YOKOE T, HAYASHIDA T, NAGAYAMA A, et al. Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis[J]. Oncologist, 2019, 24(6): e347-e357. doi: 10.1634/theoncologist.2018-0140
[15]	YAN Y J, FU J M, KOWALCHUK R O, et al. Exploration of radiation-induced lung injury, from mechanism to treatment: a narrative review[J]. Transl Lung Cancer Res, 2022, 11(2): 307-322. doi: 10.21037/tlcr-22-108
[16]	DRAKAKI A, DHILLON P K, WAKELEE H, et al. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma[J]. OncoImmunology, 2020, 9(1): 1824645. doi: 10.1080/2162402X.2020.1824645
[17]	MOUNTZIOS G, DE TOMA A, ECONOMOPOULOU P, et al. Steroid use independently predicts for poor outcomes in patients with advanced NSCLC and high PD-L1 expression receiving first-line pembrolizumab monotherapy[J]. Clin Lung Cancer, 2021, 22(2): e180-e192. doi: 10.1016/j.cllc.2020.09.017
[18]	SVATON M, ZEMANOVA M, ZEMANOVA P, et al. Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer[J]. Anticancer Res, 2020, 40(4): 2209-2217. doi: 10.21873/anticanres.14182
[19]	FUCÀ G, GALLI G, POGGI M, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors[J]. ESMO Open, 2019, 4(1): e000457. doi: 10.1136/esmoopen-2018-000457
[20]	WU M L, HUANG Q R, XIE Y, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation[J]. J Hematol Oncol, 2022, 15(1): 24. doi: 10.1186/s13045-022-01242-2
[21]	MAEDA N, MARUHASHI T, SUGIURA D, et al. Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells[J]. J Biol Chem, 2019, 294(52): 19896-19906. doi: 10.1074/jbc.RA119.010379
[22]	QUATRINI L, VACCA P, TUMINO N, et al. Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells[J]. J Allergy Clin Immunol, 2021, 147(1): 349-360. doi: 10.1016/j.jaci.2020.04.044
[23]	YANG H, XIA L, CHEN J, et al. Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity[J]. Nat Med, 2019, 25(9): 1428-1441. doi: 10.1038/s41591-019-0566-4
[24]	CAIN D W, CIDLOWSKI J A. Immune regulation by glucocorticoids[J]. Nat Rev Immunol, 2017, 17(4): 233-247. doi: 10.1038/nri.2017.1
[25]	RHEN T, CIDLOWSKI J A. Antiinflammatory action of glucocorticoids: new mechanisms for old drugs[J]. N Engl J Med, 2005, 353(16): 1711-1723. doi: 10.1056/NEJMra050541
[26]	PAULSEN O, KLEPSTAD P, ROSLAND J H, et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial[J]. J Clin Oncol, 2014, 32(29): 3221-3228. doi: 10.1200/JCO.2013.54.3926
[27]	ARROYO-HERNÁNDEZ M, MALDONADO F, LOZANO-RUIZ F, et al. Radiation-induced lung injury: current evidence[J]. BMC Pulm Med, 2021, 21(1): 9. doi: 10.1186/s12890-020-01376-4
[28]	CLARISSE D, DE BOSSCHER K. How the glucocorticoid receptor contributes to platinum-based therapy resistance in solid cancer[J]. Nat Commun, 2021, 12(1): 4959. doi: 10.1038/s41467-021-24847-6
[29]	SUZUKI K, MATSUNUMA R, MATSUDA Y, et al. A nationwide survey of Japanese palliative care physicians' practice of corticosteroid treatment for dyspnea in patients with cancer[J]. J Pain Symptom Manage, 2019, 58(6): e3-e5. doi: 10.1016/j.jpainsymman.2019.08.022
[30]	DE LA ROCHEFOUCAULD J, NOËL N, LAMBOTTE O. Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach[J]. Intern Emerg Med, 2020, 15(4): 587-598. doi: 10.1007/s11739-020-02295-2
[31]	RICCIUTI B, DAHLBERG S E, ADENI A, et al. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications[J]. J Clin Oncol, 2019, 37(22): 1927-1934. doi: 10.1200/JCO.19.00189
[32]	SKRIBEK M, ROUNIS K, AFSHAR S, et al. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors[J]. Eur J Cancer, 2021, 145: 245-254. doi: 10.1016/j.ejca.2020.12.012
[33]	DE GIGLIO A, MEZQUITA L, AUCLIN E, et al. Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (NSCLC) patients under immune-checkpoint inhibitors (ICI)[J]. Cancers, 2020, 12(10): 2827. doi: 10.3390/cancers12102827

[1]	ZHU Xiangyu, SHI Yan, FU Jing. Impact of timing of continuous renal replacement therapy on the efficacy and prognosis of patients with septic shock undergoing bundle therapy[J]. Journal of Clinical Medicine in Practice, 2024, 28(21): 66-69, 76. DOI: 10.7619/jcmp.20241850
[2]	LIU Hong. Cluster nursing for patients with gastric perforation[J]. Journal of Clinical Medicine in Practice, 2018, (18): 62-65. DOI: 10.7619/jcmp.201818019
[3]	ZHANG Fangfang, YANG Haiyan. Effect of cluster nursing intervention on rehabilitation effect and nursing quality of stroke patients[J]. Journal of Clinical Medicine in Practice, 2018, (10): 5-8,20. DOI: 10.7619/jcmp.201810002
[4]	ZHANG Fengming, TANG Menglin. Application of cluster nursing for children with severe pneumonia in ICU[J]. Journal of Clinical Medicine in Practice, 2017, (4): 141-144. DOI: 10.7619/jcmp.201704043
[5]	ZOU Huixiang, YANG Fang. Application comparison of cluster nursing and traditional nursing in children with pneumonia[J]. Journal of Clinical Medicine in Practice, 2016, (12): 130-132. DOI: 10.7619/jcmp.201612041
[6]	ZHANG Yan, WANG Jiafeng, BU Ling, LI Ting. Application of bundle nursing strategy in reduction of infection rate in patients with peritoneal dialysis[J]. Journal of Clinical Medicine in Practice, 2016, (10): 29-31. DOI: 10.7619/jcmp.201610010
[7]	YU Linlin. Effect of cluster nursing on emergency treatment of patients with severe heat stroke[J]. Journal of Clinical Medicine in Practice, 2016, (8): 34-36,46. DOI: 10.7619/jcmp.201608011
[8]	FU Hong, LI Wei, LIU Jing. Effect of cluster nursing in children with pneumonia treated by atomization inhalation[J]. Journal of Clinical Medicine in Practice, 2016, (6): 117-119. DOI: 10.7619/jcmp.201606037
[9]	LUO Yang, ZHOU Yanqun. Effect of bundled nursing on phlebitis rate induced by pediatric venous indwelling needle[J]. Journal of Clinical Medicine in Practice, 2014, (10): 129-130,135. DOI: 10.7619/jcmp.201410048
[10]	CHEN Pengying. Effect of intensive nursing on the pregnancy outcomes of puerperae with preeclampsia[J]. Journal of Clinical Medicine in Practice, 2014, (10): 71-73. DOI: 10.7619/jcmp.201410024

Cited By

Cited by

Periodical cited type(6)

1.	李月轩，王晓东，陈玮玮，田晓阳，闫鑫，李士学，裴世深. 靶点射频热凝术联合臭氧消融术治疗椎间盘源性腰痛的临床研究. 中国中医骨伤科杂志. 2025(01): 65-68+73 .
2.	孙金国. 罗哌卡因复合右美托咪定局部浸润麻醉对后路腰椎椎间融合术术后患者的影响. 反射疗法与康复医学. 2024(16): 86-88 .
3.	华海倩，李现林，张也. 通痹舒筋丸联合腰腹肌功能锻炼护理对椎间盘源性腰痛患者的影响. 护理实践与研究. 2022(18): 2685-2688 .
4.	孙晓飞，张子甲，田军涛. 低温等离子射频联合硬膜外阻滞治疗腰椎间盘突出症疗效观察. 医药论坛杂志. 2021(02): 94-97 .
5.	贺红庆，张士铭，朱丽霞. 强离子隙对扩张型心肌病患者发生心力衰竭的预测效果. 医药论坛杂志. 2021(05): 107-110 .
6.	刘姣，谭波涛，虞乐华. 腰椎间盘突出症的治疗研究进展. 保健医学研究与实践. 2020(03): 82-86 .

Other cited types(2)

Get Citation

PDF

XML

Article views (292) PDF downloads (39) Cited by(8)

Turn off MathJax

Article Contents

Abstract

References

Impact of glucocorticoids on clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer